Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Multiple myeloma cells exhibit deregulated cell cycles and rely on BCL2 family anti-apoptotic proteins.
• Cell division cycle 7 (CDC7) kinase is crucial for S-phase progression and is a target for emerging cancer therapies.
• CDC7 inhibitors can also impact CDK9, which is relevant for MCL-1 expression, a key survival protein in myeloma.

Purpose of the Study:

• To evaluate the activity and mechanism of the dual CDC7/CDK9 inhibitor PHA-767491 in multiple myeloma.
• To assess PHA-767491's efficacy in various myeloma models, including patient samples and in combination therapies.

Main Methods:

• Treatment of multiple myeloma cell lines and primary patient samples with PHA-767491.
• Assessment of PHA-767491 activity in the presence of stromal cells.
• Evaluation of combination therapy effects with melphalan, bortezomib, and doxorubicin.

Main Results:

• PHA-767491 treatment resulted in cell death across all tested multiple myeloma conditions.
• The compound demonstrated an additive effect when combined with melphalan, bortezomib, and doxorubicin.

Conclusions:

• Targeting both CDC7 and CDK9 with PHA-767491 is a promising strategy for multiple myeloma treatment.
• Further clinical assessment of dual CDC7/CDK9 inhibition in multiple myeloma is warranted.